...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Annual Financial Reporting

I really don't know what your going on about fuzzy. All I did is answer your question. The debenture is what it is. We can't change that. If HL decides to convert to common shares not much anyone can do about it unless the company pays off the $6M loan.

if you think Zenith can save the day, so be it. No problem. 

Koo

Share
New Message
Please login to post a reply